Aortic Valve Stenosis and Myocardial Efficiency – a Prognostic Marker and a Target for Intervention? - MELVAS

Aarhus University Hospital, Department of Cardiology0 个研究点开始时间: 2013年6月6日最近更新: 2016年3月14日

适应症

试验速览

暂无简介。

•- Aortic valve area <1,2 cm2 and/or transaortic maximal velocity (VmaxAO) of 3,0-5,0 m/s
•- Sinus rhythm >60/min after 5 minutes rest
•- LVEF >55%
•- Male or female
•- Age 20-100 years old
•- Safe birth control management (intrauterine devices or hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release))
•- Negative urine-HCG for women of childbearing potential
•- Ability to understand the written patient information and to give informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 30

•- Systolic BP <100 mmHg after 5 minutes of rest
•- Left ventricular posterior wall thickness >17 mm
•- Signs or history of myocardial infarction and/or severe ischemic heart disease
•- Severe asthma or chronic obstructive pulmonary disease
•- New York Heart Association (NYHA) classification > I due to AS
•- NYHA > II due to non-cardiac causes
•- 2? or 3? atrioventricular block
•- Ongoing beta-blocker therapy
•- Ongoing verapamil or diltiazem therapy
•- Ongoing monoamine oxidase inhibitors therapy
•- Sick sinus syndrome
•- Atrial fibrillation or fluttering
•- Lack of stable sinus rhythm
•- Pheochromocytoma
•- Severe peripheral vascular disease
•- Intolerance of metoprolol succinate or its excipients

发起方

Aarhus University Hospital, Department of Cardiology